logo

Calithera Biosciences Inc. (CALA)



Trade CALA now with
  Date
  Headline
11/1/2021 7:15:36 AM Calithera Presents Interim Data From Phase 1b Trial Of Arginase Inhibitor CB-280 In Cystic Fibrosis
1/4/2021 7:13:06 AM Calithera: CANTATA Study Of Telaglenastat In Renal Cell Carcinoma Did Not Achieve Primary Endpoint
10/2/2020 7:14:19 AM Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
9/24/2020 7:28:12 AM Calithera Begins KEAPSAKE Randomized Phase 2 Trial Of Telaglenastat Plus Chemoimmunotherapy
8/3/2020 7:16:21 AM Calithera Reports New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
7/13/2020 7:10:50 AM Calithera Biosciences Begins Phase 1b Trial Of Arginase Inhibitor CB-280
7/2/2020 7:15:06 AM Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/2/2020 7:11:16 AM Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/16/2020 12:38:55 AM Calithera Biosciences Prices Public Offering Of 5 Mln Shares At $6.25/Shr
1/13/2020 7:54:51 AM Calithera Expects To Utilize Cash And Investments $75 Mln-$85 Mln In 2020
1/3/2020 7:28:45 AM Calithera Biosciences Reports New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/5/2017 7:37:55 AM William Blair Initiates Calithera Biosciences Inc. (CALA) At Outperform
1/24/2017 10:01:12 AM Citigroup Ups Calithera Biosciences Inc. (CALA) To neutral From sell With -- Price Target